Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Opthea ( (AU:OPT) ) just unveiled an update.
Opthea Limited announced it will provide a corporate update on December 17, 2025, with Executive Chair Jeremy Levin hosting an online webinar for analysts and investors. This update is expected to offer insights into the company’s strategic direction and operational developments, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (AU:OPT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited is a company in the biotechnology industry, focusing on developing therapies for eye diseases. The company’s primary products or services are centered around innovative treatments for retinal diseases, with a market focus on addressing unmet medical needs in ophthalmology.
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
For a thorough assessment of OPT stock, go to TipRanks’ Stock Analysis page.